Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1985 Oct;76(4):1406–1411. doi: 10.1172/JCI112117

Abnormal factor VIII coagulant antigen in patients with renal dysfunction and in those with disseminated intravascular coagulation.

M J Weinstein, L E Chute, G W Schmitt, R H Hamburger, K A Bauer, J H Troll, P Janson, D Deykin
PMCID: PMC424088  PMID: 3932466

Abstract

Factor VIII antigen (VIII:CAg) exhibits molecular weight heterogeneity in normal plasma. We have compared the relative quantities of VIII:CAg forms present in normal individuals (n = 22) with VIII:CAg forms in renal dysfunction patients (n = 19) and in patients with disseminated intravascular coagulation (DIC; n = 7). In normal plasma, the predominant VIII: CAg form, detectable by sodium dodecyl sulfate polyacrylamide gel electrophoresis, was of molecular weight 2.4 X 10(5), with minor forms ranging from 8 X 10(4) to 2.6 X 10(5) D. A high proportion of VIII:CAg in renal dysfunction patients, in contrast, was of 1 X 10(5) mol wt. The patients' high 1 X 10(5) mol wt VIII: CAg level correlated with increased concentrations of serum creatinine, F1+2 (a polypeptide released upon prothrombin activation), and with von Willebrand factor. Despite the high proportion of the 1 X 10(5) mol wt VIII:CAg form, which suggests VIII:CAg proteolysis, the ratio of Factor VIII coagulant activity to total VIII:CAg concentration was normal in renal dysfunction patients. These results could be simulated in vitro by thrombin treatment of normal plasma, which yielded similar VIII:CAg gel patterns and Factor VIII coagulant activity to antigen ratios. DIC patients with high F1+2 levels but no evidence of renal dysfunction had an VIII:CAg gel pattern distinct from renal dysfunction patients. DIC patients had elevated concentrations of both the 1 X 10(5) and 8 X 10(4) mol wt VIII:CAg forms. We conclude that an increase in a particular VIII:CAg form correlates with the severity of renal dysfunction. The antigen abnormality may be the result of VIII:CAg proteolysis by a thrombinlike enzyme and/or prolonged retention of proteolyzed VIII:CAg fragments.

Full text

PDF
1406

Images in this article

1407Image
on p.1407
1407Image
on p.1407

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauer K. A., Rosenberg R. D. Thrombin generation in acute promyelocytic leukemia. Blood. 1984 Oct;64(4):791–796. [PubMed] [Google Scholar]
  2. Esmon C. T. The subunit structure of thrombin-activated factor V. Isolation of activated factor V, separation of subunits, and reconstitution of biological activity. J Biol Chem. 1979 Feb 10;254(3):964–973. [PubMed] [Google Scholar]
  3. Hultin M. B., Jesty J. The activation and inactivation of human factor VIII by thrombin: effect of inhibitors of thrombin. Blood. 1981 Mar;57(3):476–482. [PubMed] [Google Scholar]
  4. Janson P. A., Jubelirer S. J., Weinstein M. J., Deykin D. Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med. 1980 Dec 4;303(23):1318–1322. doi: 10.1056/NEJM198012043032302. [DOI] [PubMed] [Google Scholar]
  5. LANGDELL R. D., WAGNER R. H., BRINKHOUS K. M. Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure. J Lab Clin Med. 1953 Apr;41(4):637–647. [PubMed] [Google Scholar]
  6. Laudano A. P., Doolittle R. F. Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization. Structural requirements, number of binding sites, and species differences. Biochemistry. 1980 Mar 4;19(5):1013–1019. doi: 10.1021/bi00546a028. [DOI] [PubMed] [Google Scholar]
  7. Laurell C. B. Electroimmuno assay. Scand J Clin Lab Invest Suppl. 1972;124:21–37. doi: 10.3109/00365517209102748. [DOI] [PubMed] [Google Scholar]
  8. Mannucci P. M., Remuzzi G., Pusineri F., Lombardi R., Valsecchi C., Mecca G., Zimmerman T. S. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med. 1983 Jan 6;308(1):8–12. doi: 10.1056/NEJM198301063080102. [DOI] [PubMed] [Google Scholar]
  9. Milani L., Merkel C., Canel F., Gasparotto M. L., Gatta A. Relationship between plasma levels of factor VIII related antigen and reticulo-endothelial function in chronic uremia. Clin Nephrol. 1983 Nov;20(5):235–238. [PubMed] [Google Scholar]
  10. Moake J. L., Byrnes J. J., Troll J. H., Rudy C. K., Weinstein M. J., Colannino N. M., Hong S. L. Abnormal VIII: von Willebrand factor patterns in the plasma of patients with the hemolytic-uremic syndrome. Blood. 1984 Sep;64(3):592–598. [PubMed] [Google Scholar]
  11. RAPAPORT S. I., SCHIFFMAN S., PATCH M. J., AMES S. B. The importance of activation of antihemophilic globulin and proaccelerin by traces of thrombin in the generation of intrinsic prothrombinase activity. Blood. 1963 Feb;21:221–236. [PubMed] [Google Scholar]
  12. Teitel J. M., Bauer K. A., Lau H. K., Rosenberg R. D. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex. Blood. 1982 May;59(5):1086–1097. [PubMed] [Google Scholar]
  13. Toole J. J., Knopf J. L., Wozney J. M., Sultzman L. A., Buecker J. L., Pittman D. D., Kaufman R. J., Brown E., Shoemaker C., Orr E. C. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature. 1984 Nov 22;312(5992):342–347. doi: 10.1038/312342a0. [DOI] [PubMed] [Google Scholar]
  14. Vehar G. A., Davie E. W. Preparation and properties of bovine factor VIII (antihemophilic factor). Biochemistry. 1980 Feb 5;19(3):401–410. doi: 10.1021/bi00544a001. [DOI] [PubMed] [Google Scholar]
  15. Vehar G. A., Keyt B., Eaton D., Rodriguez H., O'Brien D. P., Rotblat F., Oppermann H., Keck R., Wood W. I., Harkins R. N. Structure of human factor VIII. Nature. 1984 Nov 22;312(5992):337–342. doi: 10.1038/312337a0. [DOI] [PubMed] [Google Scholar]
  16. Warrell R. P., Jr, Hultin M. B., Coller B. S. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in renal failure. Am J Med. 1979 Feb;66(2):226–228. doi: 10.1016/0002-9343(79)90531-x. [DOI] [PubMed] [Google Scholar]
  17. Weinstein M. J., Chute L. E. Two distinct forms of Factor VIII coagulant protein in human plasma. Cleavage by thrombin, and differences in coagulant activity and association with von Willebrand factor. J Clin Invest. 1984 Feb;73(2):307–316. doi: 10.1172/JCI111215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Weinstein M. J., Fulcher C. A., Chute L. E., Zimmerman T. S. Apparent molecular weight of purified human factor VIII procoagulant protein compared with purified and plasma factor VIII procoagulant protein antigen. Blood. 1983 Nov;62(5):1114–1117. [PubMed] [Google Scholar]
  19. Weinstein M., Chute L., Deykin D. Analysis of factor VIII coagulant antigen in normal, thrombin-treated, and hemophilic plasma. Proc Natl Acad Sci U S A. 1981 Aug;78(8):5137–5141. doi: 10.1073/pnas.78.8.5137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Weiss H. J., Baumgartner H. R., Tschopp T. B., Turitto V. T., Cohen D. Correction by factor VIII of the impaired platelet adhesion to subendothelium in von Willebrand disease. Blood. 1978 Feb;51(2):267–279. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES